Dianthus Therapeutics Inc DE
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(c) Trading Plans. The following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act) or director who entered into, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended March 31, 2025:
| Name (Tile) | Action Taken (Date of Action) | Nature of Trading Arrangement | Type of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Marino Garcia (President and Chief Executive Officer) | Adoption (March 17, 2025) | Sale | Rule 10b5-1 trading arrangement | Through and including December 31, 2025 | Up to 70,000 shares |
| Ryan Savitz(Chief Financial Officer and Chief Business Officer) | Adoption (March 31, 2025) | Sale | Rule 10b5-1 trading arrangement | Through and including December 31, 2025 | Up to 60,000 shares |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.